Trost DACH-Phenyl Ligand in Asymmetric Allylic Alkylation: API Synthesis Applications

April 30, 2026 Applications, Industry Trost, DACH, allylic alkylation, palladium, API, chiral

The Trost modular ligand family, based on trans-1,2-diaminocyclohexane (DACH) backbone with tartaric-acid-derived bridging groups, is the privileged scaffold for palladium-catalyzed asymmetric allylic alkylation (AAA). The DACH-phenyl variant, in which the bridge bears phenyl substituents, is among the most commercially important members of the family and a top seller in the chiral ligand market due to its deployment in active pharmaceutical ingredient (API) routes.

Reaction Manifold

Trost AAA builds C–C, C–N, C–O, and C–S bonds at the allylic position with high enantioselectivity. The Pd(0)–DACH-phenyl complex forms a π-allyl intermediate that is attacked by a stabilized nucleophile (malonate, amine, phenoxide) on the face dictated by the ligand’s chiral pocket.

Why DACH-Phenyl Dominates

  • Predictable sense of induction: The (R,R) ligand reliably delivers one enantiomer across substrate classes.
  • Hard/soft nucleophile tolerance: Works with both “hard” alkoxides and “soft” malonates.
  • Dynamic kinetic resolution: Meso and racemic substrates can be desymmetrized.
  • Documented scale-up: Demonstrated to multi-ton scale in commercial API manufacture.

API Synthesis Cases

The DACH-phenyl Trost ligand is cited in published routes to antivirals, oncology drugs, and central nervous system agents. Notably, the technology underpins the enantioselective construction of all-carbon quaternary centers — a common challenge in modern drug design — and is a frequent choice when asymmetric hydrogenation cannot access the target stereocenter directly.

Selecting the Enantiomer

Both the (R,R)-DACH-phenyl and (S,S)-DACH-phenyl enantiomers are routinely used. Process chemists stock both because the absolute configuration of the desired API may require either ligand depending on substrate geometry.

Market Context

The Trost DACH-phenyl ligand has been a top-10 selling chiral ligand for the past five years, driven by its documented regulatory acceptance and the growing demand for enantioselective allylic substitution in late-stage functionalization campaigns.

Back to Documents